RxDoctor Payments Data

Christopher Yamamoto, MD

Family Medicine · Calhoun, GANPI 1164586004

Payments from drug & device makers

$6,428in general payments, 2019–2025

Across 399 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$941
  • Pfizer$921
  • AbbVie$759
  • GSK$423
  • Amgen$385
  • Lilly USA, LLC$330
  • plus $3K from 38 others

What the payments were for

  • Food & beverage$6,422100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$6,428 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$183,473
Medicare patients
428
Services billed
3,462

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban197$180,639
Trelegy ElliptaFluticasone/Umeclidin/Vilanter147$137,058
OzempicSemaglutide96$108,532
XareltoRivaroxaban44$47,598
JardianceEmpagliflozin40$38,448
JanuviaSitagliptin Phosphate27$29,277
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog56$23,846
LinzessLinaclotide25$20,839
MyrbetriqMirabegron27$20,275
Breo ElliptaFluticasone/Vilanterol34$15,216
MounjaroTirzepatide14$14,861
Nurtec OdtRimegepant Sulfate15$14,577
GemtesaVibegron24$11,072
Lantus SolostarInsulin Glargine,hum.Rec.Anlog79$11,067
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,649

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Nurtec Odt$921$195,216212 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$423$160,923199 claims
Novo NordiskOzempic$941$108,53296 claims
Johnson & JohnsonXarelto$69$47,59844 claims
Boehringer IngelheimJardiance$204$38,44840 claims
MerckJanuvia$200$29,27727 claims
AbbVieLinzess, Synthroid$759$24,50676 claims
Astellas Pharma US IncMyrbetriq$51$20,27527 claims
Lilly USA, LLCMounjaro$330$14,86114 claims
Sumitomo Pharma America, Inc.Gemtesa$67$11,07224 claims
AstraZenecaBreztri Aerosphere$274$7,52612 claims
Sanofi-aventis U.S. LLCLantus$156$2,32218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Calhoun

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →